Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,541 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infant Clear all
Completed Not applicable Interventional Results available

A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy

NCT00294684
View directory record Official record
Conditions
Biliary Atresia
Interventions
Corticosteroids, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 6 Months
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Not applicable Interventional Results available

MOMSonLINE2 ; A Pilot Study Testing Recruitment and Retention of Women of Color to an Online Support Group for Bereaved Mothers

NCT04600076
View directory record Official record
Conditions
Stillbirth, Grief, Infant Death
Interventions
BabyCenter site and the community group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 21, 2026, 10:56 PM EDT
Completed No phase listed Observational

T Cell Memory Fuels the Innate Response in Chronic CF Lung Disease

NCT04397861
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 3 Interventional

Post-hospitalization Nursing Effectiveness (PHONE) Study

NCT00314431
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Prematurity
Interventions
Care coordination by telephone contacts with a nurse
Procedure
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 483 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

NCT03765073
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 40 Years
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 21, 2026, 10:56 PM EDT
Terminated Not applicable Interventional

Delayed Cord Clamping in Very Low Birth Weight Infants

NCT02337088
View directory record Official record
Conditions
Very Low Birth Weight Infants, Premature Infants, Intraventricular Hemorrhage
Interventions
Delayed cord clamping at 30 seconds, Delayed cord clamping at 60 seconds
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 21, 2026, 10:56 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Tiny Tummies - A Milk Study

NCT07839156
View directory record Official record
Conditions
Gut Microbiome, Neurocognitive Correlates of Eating Habits, Infants and Young Children, Sleep
Interventions
Daily cow's milk products, Daily Oat Milk Exposure
Other
Lead sponsor
Arizona State University
Other
Eligibility
6 Months to 12 Months
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 4 Interventional Results available

Pragmatic Research on Diuretic Management in Early BPD Pilot

NCT05898022
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Furosemide (plus potassium chloride), Placebo (plus placebo electrolyte solution)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Weeks to 10 Weeks
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age

NCT00726102
View directory record Official record
Conditions
Nutritional Deficiencies
Interventions
Meat, Cereal, fortified rice cereal
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 18 Months
Enrollment
1,488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

NCT03396588
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Morphine
Drug
Lead sponsor
Henrietta Bada
Other
Eligibility
12 Hours to 7 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Hydroxychloroquine in Cystic Fibrosis

NCT00311883
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hydroxychloroquine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2008 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Results available

The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants

NCT00167388
View directory record Official record
Conditions
Anemia of Prematurity
Interventions
feed during blood transfusion
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Weeks to 38 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 10:56 PM EDT
Completed No phase listed Observational Results available

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

NCT02287688
View directory record Official record
Conditions
Meningococcal Disease, Infections, Meningococcal
Interventions
Meningococcal quadrivalent CRM-197 conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months to 23 Months
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 21, 2026, 10:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants

NCT00833222
View directory record Official record
Conditions
Premature Birth
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
31 Weeks to 42 Weeks
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

NCT00944073
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 21, 2026, 10:56 PM EDT
Recruiting Phase 2 Interventional

Lipid Infusions to Optimize Nutrition Trial

NCT06915441
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Neurodevelopmental Impairment
Interventions
SOLE, MOLE
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
12 Hours to 28 Weeks
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 10:56 PM EDT
Enrolling by invitation Phase 3 Interventional

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
1 Year and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 10:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin

NCT01207778
View directory record Official record
Conditions
Prematurity
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
36 Months to 72 Months
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
3
States / cities
Albuquerque, New Mexico • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

NCT02412111
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Tezacaftor/Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

NCT00694109
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
Mipomersen Sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
20
States / cities
Mission Viejo, California • Newport Beach, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 21, 2026, 10:56 PM EDT
Recruiting Not applicable Interventional

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

NCT06175104
View directory record Official record
Conditions
Heart Defects, Congenital, Anxiety in Pregnancy, Depression, Postpartum, Trauma, Psychological, Neurodevelopmental Disorders
Interventions
HeartGPS
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 21, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
48
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 10:56 PM EDT